Nonlamellar lyotropic liquid crystalline (LLC) nanoparticles
are
a family of versatile nano-self-assemblies, which are finding increasing
applications in drug solubilization and targeted drug delivery. LLC
nanodispersions are heterogeneous with discrete nanoparticle subpopulations
of distinct internal architecture and morphology, frequently coexisting
with micelles and/or vesicles. Diversity in the internal architectural
repertoire of LLC nanodispersions grants versatility in drug solubilization,
encapsulation, and release rate. However, drug incorporation contributes
to the heterogeneity of LLC nanodispersions, and on exposure to biological
media, LLC nanodispersions often undergo nanostructural and morphological
transformations. From a pharmaceutical perspective, coexistence of
multiple types of nanoparticles with diverse structural attributes,
together with media-driven transformations in colloidal characteristics,
brings challenges in dissecting biological and therapeutic performance
of LLC nanodispersions in a spatiotemporal manner. Here, we outline
innate and acquired heterogeneity of LLC nanodispersions and discuss
technological developments and alternative approaches needed to improve
homogeneity of LLC formulations for drug delivery applications.